公司全年实现营业收入7.68亿元，同比增长3.26%；归母净利润0.79亿元，同比下降23.55%。收入仍在增 长，但利润却出现明显下滑——当营收与利润开始"反向走"，问题往往不在市场，而在成本结构。 整体来看，公司处于 "收入稳、利润降"的典型阶段 ，增长质量短期受到影响。 利润下滑核心：研发投入与折旧摊销提升 利润承压的核心原因主要来自成本端和费用端的上升。 2026年2月27日， 翔宇医疗（688626） 发布2025年业绩快报： 一方面，公司持续加大研发投入，引进高端康复技术人才，研发人员薪酬及相关费用增加，带动整体费用 上行。 另一方面，随着前期建设项目陆续投入使用，折旧与摊销费用明显增加，对利润形成持续压制。 在此背景下，公司虽然维持了收入增长，但利润端被"费用扩张"显著侵蚀，尤其扣非净利润降幅达到 34.48%，反映主营盈利能力的实际压力更为明显。 | | | 81 | | --- | --- | --- | | V | 12 | | | . 1.0 | | | | | | . | | IL | | | | 1 1 | | 1 | | 项目 | 本报告期 | 上年同期 | 增减变动幅度(%) | ...

Group 1: Company Overview - The report covers Damai Entertainment (1060.HK), a leading platform in live entertainment, driven by ticketing and IP derivatives [1][6][8] - The company is positioned in a high-growth sector, benefiting from the recovery and structural upgrade of offline entertainment consumption [1][8] - Expected adjusted net profits for FY26-28 are projected at 1.06 billion, 1.35 billion, and 1.58 billion CNY respectively [1][8] Group 2: Industry Insights - The live performance market is experiencing a significant increase, with ticket sales for large concerts expected to exceed 26 billion CNY in 2024, a year-on-year growth of 78.1% [6] - The demand for live entertainment is driven by both personal enjoyment and social needs, with an increase in repeat attendance [6] - The supply side is expanding with diversification in lower-tier cities and various performance categories [6] Group 3: IP Business - Alibaba's IP licensing platform, Aliyu, is a leading player in the market, with a projected GMV of 4.1 billion USD in 2024 [7] - The company is enhancing its collaboration with top IPs, which is expected to contribute significantly to revenue growth [7] - The film industry is still in a recovery phase, with a total box office of 29.23 billion CNY in the first half of 2025, reflecting a year-on-year increase of 22.91% [7] Group 4: Company Financials - Sinopec Engineering (02386.HK) is highlighted as a leading energy and chemical engineering firm with strong technical capabilities and a solid financial performance [10][12] - The company has a high dividend payout ratio, with a dividend yield exceeding 5%, providing stable returns for investors [10][12] - Expected target price for 2026 is set at 9.50 HKD per share, based on a 13x PE ratio [10] Group 5: Market Trends - The petrochemical industry is facing revenue stability but profit pressures, with a slight revenue decline of 2.6% year-on-year in H1 2025 [11] - The trend of "reducing oil and increasing chemicals" is evident, with a 9.94% year-on-year increase in ethylene consumption [11] - Global refining capacity continues to grow, particularly in the Middle East and Asia-Pacific regions, with a projected capital expenditure of 153.35 billion USD in 2024 [11] Group 6: Aviation Sector - Bank of China Aviation Leasing (02588.HK) is positioned to benefit from the rising aviation industry and the ongoing interest rate cut cycle [14][15] - The company ranks fifth globally with a fleet of 483 aircraft, poised to gain from increased revenues as the aviation market recovers [14][15] - Expected total revenue for 2025-2027 is projected at 2.63 billion, 2.85 billion, and 2.94 billion USD, with net profits of 761 million, 894 million, and 964 million USD respectively [16] Group 7: Medical Sector - Weisi Medical (688580.SH) is experiencing steady growth, with projected net profits of 133 million, 165 million, and 184 million CNY for 2025-2027 [4][18] - The company focuses on rehabilitation as its core business while expanding into aesthetic and urology sectors [18][19] - The company emphasizes product innovation in non-invasive brain-machine interfaces, aiming to create a comprehensive neuro-rehabilitation system [19]

Group 1: Industry Development - The government emphasizes the need for industrial transformation and upgrading in Anyang to inject new momentum into regional economic development [3] - Liu Ning highlights the importance of increasing R&D investment in the smart connected new energy commercial vehicle industry to promote energy-saving and carbon reduction across the entire production process [3] - The focus is on enhancing technical innovation and accelerating the R&D of high-end products like high magnetic permeability silicon steel to create a leading advantage in niche markets [3] Group 2: Agricultural Production - Liu Ning stresses the importance of ensuring food security and implementing precise measures for winter wheat management, especially given the late autumn sowing this year [4] - The need to enhance agricultural social service capabilities by integrating advanced agricultural machinery with farming practices is highlighted [3] Group 3: Cultural and Tourism Development - The government aims to fully utilize Anyang's rich cultural heritage to develop high-quality tourism routes and cultural landmarks, promoting traditional Chinese culture [4] - There is a push to transform the cultural tourism industry into a pillar industry by making cultural relics more accessible and engaging [4]

Group 1: Industry Development - The city of Anyang is accelerating industrial transformation and upgrading to inject new momentum into regional economic development [3] - Liu Ning emphasized the need for increased R&D investment in the smart connected new energy commercial vehicle industry, promoting energy-saving and carbon-reducing processes [3] - Liu Ning praised the efforts of Anyang Steel's subsidiary in transforming the steel industry and encouraged further technological innovation and development of high-end products [3] Group 2: Agricultural Development - Liu Ning highlighted the importance of advanced agricultural machinery and the need to cultivate more advanced agricultural equipment enterprises to enhance agricultural social services [3] - The focus is on integrating agricultural machinery with farmland and agronomy to improve efficiency [3] - Liu Ning stressed the importance of ensuring food security and implementing precise measures for winter wheat management [4] Group 3: Cultural and Tourism Development - Liu Ning called for the full utilization of cultural resources in Anyang to develop high-quality tourism routes and cultural landmarks [4] - The aim is to promote traditional Chinese culture and develop the cultural tourism industry into a pillar industry [4]

伟思医疗方面表示，本次交易预计对公司2026年度归属于上市公司股东的净利润影响金额约为1000万元 （未经审计），对2025年当期营业收入及净利润无任何影响。公司全新总部——"伟思医疗总部研发经 济园"（位于南京市雨花台区硕果路1号）已顺利通过竣工验收，全面具备高效办公与运营条件，公司计 划于2026年上半年完成整体搬迁。 伟思医疗主要产品为康复医疗设备。2025年前三季度，伟思医疗营业收入为3.26亿元，同比增长 11.58%；归属于上市公司股东的净利润为1.02亿元，同比增长30.68%。中经记者 晏国文 卢志坤 北京报 道 【伟思医疗拟1.19亿元卖房 将影响2026年业绩1000万元】12月22日晚，科创板上市公司伟思医疗 （688580.SH）发布公告称，拟以总价1.19亿元的价格，将现在的总部资产转让给江苏云智汇创业投资 有限公司，目的在优化资产结构、提升资源配置效率并增强资金流动性。 伟思医疗此次拟转让的资产是南京市雨花台区宁双路19号9幢的房屋及楼宇部分配套固定资产。 该资产截至2025年9月30日的账面净值为7994.86万元。 ...

伟思医疗主要产品为康复医疗设备。2025年前三季度，伟思医疗营业收入为3.26亿元，同比增长 11.58%；归属于上市公司股东的净利润为1.02亿元，同比增长30.68%。 该资产截至2025年9月30日的账面净值为7994.86万元。 伟思医疗方面表示，本次交易预计对公司2026年度归属于上市公司股东的净利润影响金额约为1000万元 （未经审计），对2025年当期营业收入及净利润无任何影响。公司全新总部——"伟思医疗总部研发经 济园"（位于南京市雨花台区硕果路1号）已顺利通过竣工验收，全面具备高效办公与运营条件，公司计 划于2026年上半年完成整体搬迁。 12月22日晚，科创板上市公司伟思医疗（688580.SH）发布公告称，拟以总价1.19亿元的价格，将现在 的总部资产转让给江苏云智汇创业投资有限公司，目的在优化资产结构、提升资源配置效率并增强资金 流动性。 伟思医疗此次拟转让的资产是南京市雨花台区宁双路19号9幢的房屋及楼宇部分配套固定资产。 （文章来源：中国经营报） ...

Core Insights - On August 13, Weisi Medical's stock closed at 56.00 yuan, an increase of 0.14 yuan, representing a 0.25% rise [1] - The trading volume for the day was 48,657 hands, with a transaction amount of 270 million yuan, resulting in a turnover rate of 5.08% [1] - Weisi Medical operates in the medical device sector, focusing on the research, production, and sales of medical equipment, including rehabilitation medical devices and surgical instruments [1] Financial Performance - On August 13, the net outflow of main funds for Weisi Medical was 14.5931 million yuan, with a cumulative net outflow of 8.8830 million yuan over the past five days [1] - The overall performance of the medical device sector on that day was poor, with several related stocks experiencing declines [1]

Group 1 - The core stock price of Xiangyu Medical as of August 6, 2025, is 52.80 yuan, reflecting a decrease of 1.18% from the previous trading day, with a trading volume of 294 million yuan and a turnover rate of 3.48% [1] - Xiangyu Medical operates in the medical device sector, focusing on the research, production, and sales of rehabilitation medical equipment, providing comprehensive rehabilitation solutions for medical institutions [1] - The company is actively advancing the integration of its self-developed brain-computer interface products with its rehabilitation equipment, aiming to create a complete brain-computer interface solution and gradually promote it to various levels of medical institutions [1] Group 2 - Currently, related products are undergoing clinical trials at multiple centers to verify their effectiveness compared to traditional rehabilitation methods [1] - On August 6, the net outflow of main funds for Xiangyu Medical was 17.81 million yuan, with a cumulative net outflow of 34.79 million yuan over the past five days [1]

翔宇医疗属于医疗器械板块，公司主营业务为医疗器械的研发、生产和销售。公司产品涵盖多个医疗领 域，包括康复医疗设备等。 截至2025年7月31日收盘，翔宇医疗股价报46.00元，较前一交易日下跌0.55元，跌幅1.18%。当日成交 量为49334手，成交金额达2.27亿元。 来源:金融界 风险提示：股市有风险，投资需谨慎。 从资金流向来看，翔宇医疗7月31日主力资金净流出2320.53万元，占流通市值的0.32%。近期医疗器械 行业受到政策关注，国家医保局新设多项医疗新技术相关价格项目，包括脑机接口等创新技术。 ...